KX-826 users: 0.5% vs 0.9% vs foam Technology 8/3/2025
KX-826 is being discussed for hair loss treatment, with users debating between 0.5% and 0.9% solutions and foam. Some report side effects like headaches, while others see no changes; it blocks androgen receptors without reducing DHT levels.
View this post in the Community →
Similar Community Posts Join
5 / 413 resultscommunity If we lose hair because of our sensitivity to DHT, then why are we trying to reduce DHT when our sensitive androgen receptors are the culprit?
The conversation discusses the effectiveness of reducing DHT for hair loss treatment and explores alternative approaches like reducing androgen receptor sensitivity. Specific treatments mentioned include finasteride, dutasteride, pyrilutamide (KX-826), GT20029, and RU58841.
community Kintor’s KX-826 Pyrilutamide!!
KX-826 hair loss treatment completed trials with mild side effects. GT20029 may be ultimate cure, destroying androgen receptors causing baldness.
community How much faith do you have in Kintor?
KX-826 is a potential hair loss treatment, with users discussing its effectiveness compared to finasteride and concerns about its trial results. Some users express skepticism about new treatments, while others discuss the potential of androgen receptor degraders and the need to manage drug resistance.
community Any treatment not nuking systemic DHT levels?
Hair loss treatments that avoid significantly lowering systemic DHT levels, focusing on topical options like dutasteride mesotherapy, minoxidil, and ketoconazole. The user is exploring alternatives like KX-826 and RU58841 due to concerns about hormone levels.
community KX-826 , a small change in the pipeline
KX-826 is undergoing trials for hair loss treatment, showing similar effectiveness between 0.5% and 1.0% dosages, with mild side effects compared to finasteride. Users discuss combining KX-826 with other treatments like minoxidil and clascoterone for better results.
Related Research
6 / 185 results
research Development and Validation of Androgen-induced Hair Loss and Anagen Induction Mouse Models for Pharmacological Evaluation of Anti-Androgenic Agents
The mouse models are effective for testing new hair loss treatments.
research Mechanism exploration of the combined use of minoxidil with natural compounds ginsenoside Rg3 and glycyrrhizic acid for enhancing androgenic alopecia therapy
Combining minoxidil with ginsenoside Rg3 and glycyrrhizic acid offers a more effective treatment for androgenic alopecia.
research A decade of progress in androgenetic alopecia management: Emerging therapies and multimodal strategies
Androgenetic alopecia treatments are becoming more personalized and include new therapies like topical antiandrogens and regenerative strategies.
research Androgenetic Alopecia: Therapy Update
There are many treatments for common hair loss, but more trials are needed to decide which are best.
research Topical solutions for androgenetic alopecia: evaluating efficacy and safety
Topical treatments for hair loss can be effective but need careful safety evaluation.
research Promises and Pitfalls of Regenerative Therapies for Androgenetic Alopecia: Platelet-Rich Plasma, Photobiomodulation, Stem Cells, and Exosomes
Regenerative therapies show promise for hair regrowth, but more research and standardization are needed.